OmniComm Systems to be Acquired by Anju Software


Applied Clinical Trials

OmniComm Systems, Inc., a strategic software solutions provider to the life sciences industry, has announced that it has entered into a merger agreement with Anju Software, Inc. Under the terms of the agreement, OmniComm will become a wholly owned subsidiary of Anju. Upon closing, shares of OmniComm common stock will be cancelled and automatically converted into the right to receive $0.41032 per share, without interest, representing an 58% premium to the closing price on July 15, 2019.

Anju is a provider of data and application software to life sciences companies, contract research organizations, and medical device manufacturers. Anju’s software aides in workflow management, data collection, communications management, and decision-making processes throughout the life sciences value chain. OmniComm’s solutions, including its TrialMaster and TrialOne products, will complement Anju’s existing solution suite.

“Our merger with Anju represents the next chapter in OmniComm’s evolution, starting as a systems integrations company and growing into a global provider of software and services for the Life Sciences community,” commented Randall Smith, Founder and Executive Vice Chairman of OmniComm. “OmniComm will help bolster Anju’s current product portfolio and we believe that Anju’s customer base will embrace OmniComm’s eClinical solutions, helping to accelerate growth.”

Stockholders of OmniComm holding at least a majority of the outstanding shares of voting stock have approved the merger agreement by written consent, and the closing is expected to occur by October 31, 2019 following the satisfaction of customary closing conditions.

Crosstree Capital Securities, LLC served as OmniComm’s financial advisor and Foley & Lardner LLP served as OmniComm’s legal counsel in the transaction. Madison Park Group LLC served as Anju’s financial advisor and Snell & Wilmer LLP served as Anju’s legal counsel in the transaction.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.